Jade Biosciences (NASDAQ:JBIO – Get Free Report) and Oculis (NASDAQ:OCS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.
Profitability
This table compares Jade Biosciences and Oculis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jade Biosciences | N/A | -51.96% | -47.65% |
| Oculis | -13,958.12% | -90.31% | -67.85% |
Volatility and Risk
Jade Biosciences has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jade Biosciences | N/A | N/A | -$69.63 million | ($30.33) | -0.26 |
| Oculis | $780,000.00 | 970.04 | -$97.43 million | ($2.67) | -6.49 |
Jade Biosciences has higher earnings, but lower revenue than Oculis. Oculis is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations for Jade Biosciences and Oculis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jade Biosciences | 0 | 0 | 3 | 0 | 3.00 |
| Oculis | 0 | 0 | 4 | 0 | 3.00 |
Jade Biosciences presently has a consensus price target of $16.00, indicating a potential upside of 101.26%. Oculis has a consensus price target of $35.75, indicating a potential upside of 106.29%. Given Oculis’ higher probable upside, analysts clearly believe Oculis is more favorable than Jade Biosciences.
Institutional and Insider Ownership
22.3% of Oculis shares are held by institutional investors. 24.9% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Jade Biosciences beats Oculis on 7 of the 12 factors compared between the two stocks.
About Jade Biosciences
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
